Alexander E. Perl

Also affiliated with University of Pennsylvania

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Cytokine-mediated CAR T therapy resistance in AML”.

Cytokine-mediated CAR T therapy resistance in AML

Nature Medicine(2024)10.1038/s41591-024-03271-5

N/A

2.2DataRank · unranked

90 citations

Leonel Torres, Olga Shestova, Maksim Shestov, Patrick Mellors, Han R Fisher +24 more

Multiomic single cell sequencing identifies stemlike nature of mixed phenotype acute leukemia

Nature Communications(2024)10.1038/s41467-024-52317-2

N/A

0.537DataRank · unranked

17 citations

Vanessa E. Kennedy, Anushka Walia, Cyrille L. Delley, Andrew Koh, Elaine Tran +17 more

Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients

Transplantation and Cellular Therapy(2024)10.1016/j.jtct.2024.01.062

N/A

0.434DataRank · unranked

17 citations

Thuy T. Koll, Shannon Gier, Alessandro Racioppi, Griffin White, M. Lew +22 more

Multiomic Single Cell Sequencing Identifies Stemlike Nature of Mixed Phenotype Acute Leukemia and Provides Novel Risk Stratification

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.05.15.540305

N/A

0.241DataRank · unranked

4 citations

Vanessa E. Kennedy, Anushka Walia, Cyrille L. Delley, Andrew Koh, Elaine Tran +12 more

Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia

Haematologica(2024)10.3324/haematol.2024.285275

N/A

0DataRank · unranked

2 citations

Neeharika Prathapa, Noelle V. Frey, Saar Gill, Elizabeth O. Hexner, Ximena Bruno +13 more

Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations

Blood Advances(2020)10.1182/bloodadvances.2019000919

N/A

0DataRank · unranked

78 citations

Jason E. Hill, Leena Rahmat, Alexander E. Perl, Erkut Bahceci, Kenichi Mori +2 more

Evolving racial/ethnic disparities in AML survival in the novel therapy era

Blood Advances(2025)10.1182/bloodadvances.2024014127

N/A

0DataRank · unranked

14 citations

Phyllis A. Gimotty, Andrew Matthews, Ronac Mamtani, Selina M. Luger, Elizabeth O. Hexner +15 more

Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL

Journal of Clinical Investigation(2020)10.1172/jci134424

N/A

0DataRank · unranked

58 citations

Gerald Wertheim, Joseph P. Loftus, Daniel Blumenthal, Anne W. Lehman, Yong Li +8 more

Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib

Blood Advances(2021)10.1182/bloodadvances.2020003398

N/A

0DataRank · unranked

40 citations

Lisa H.F. McGary, Tanya Kumar, Hunter Jackson, Jose Jacob, Robert Durruthy-Durruthy +5 more

The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib

American Journal of Hematology(2023)10.1002/ajh.27096

N/A

0DataRank · unranked

9 citations

Janét Pittsenbarger, Vanessa E. Kennedy, Cheryl A.C. Peretz, Alexander E. Perl, Catherine C. Smith +4 more